GMP-Compliant Manufacturing of TRUCKs: CAR T Cells targeting GD(2) and Releasing Inducible IL-18

Chimeric antigen receptor (CAR)-engineered T cells can be highly effective in the treatment of hematological malignancies, but mostly fail in the treatment of solid tumors. Thus, approaches using 4(th) advanced CAR T cells secreting immunomodulatory cytokines upon CAR signaling, known as TRUCKs (“T...

Descripción completa

Detalles Bibliográficos
Autores principales: Glienke, Wolfgang, Dragon, Anna Christina, Zimmermann, Katharina, Martyniszyn-Eiben, Alexandra, Mertens, Mira, Abken, Hinrich, Rossig, Claudia, Altvater, Bianca, Aleksandrova, Krasimira, Arseniev, Lubomir, Kloth, Christina, Stamopoulou, Andriana, Moritz, Thomas, Lode, Holger N., Siebert, Nikolai, Blasczyk, Rainer, Goudeva, Lilia, Schambach, Axel, Köhl, Ulrike, Eiz-Vesper, Britta, Esser, Ruth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8988144/
https://www.ncbi.nlm.nih.gov/pubmed/35401506
http://dx.doi.org/10.3389/fimmu.2022.839783

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8988144/
https://www.ncbi.nlm.nih.gov/pubmed/35401506
http://dx.doi.org/10.3389/fimmu.2022.839783

Ejemplares similares